From what I remember it didn't not have very problematic statements regarding GET/CBT or psychosomatic theories. But it was also not very precise on biomedical research findings (frequent overstatements).
Would be interesting to see the results of the ME/CFS groups combined (mild-moderate and severe) versus controls. I couldn't easily find that in the paper or supplementary material.
I couldn't find the dataset there, anyone been able to find it?
Happen to be reading this older 2018 study, great to see that there's already a S4ME thread for it.
Although this meta-analysis found an effect, for most antidepressants it was notably small. The paper states:
This is an overview from the supplementary material (page 150). For Prozac...
Here's how they describe the intervention. It looks like pacing but in rehabilitation and CBT-context. I doubt it will be successful. IMHO pacing is more a way of coping than an effective intervention.
So changing one data point makes the result statistically insignificant? Whatever the right version of the dataset, it's clear that these results aren't very robust.
Agree it looks like more than one dot to me. I suspect it's easier to make a mistake in the text and p-value calculation than plot a wrong data point like this. So I wonder if the plot might be the correct version.
These seem to be the main results for EBV. Notable that the seniors had similarly elevated viral load. So perhaps it was mostly the control group that was unusual?
Perhaps a stupid question but isn't it more likely that menstruation caused symptoms in addition to ME/CFS symptoms, rather than exacerbating those? In that case it wouldn't not tell use more about ME/CFS pathology.
Instead of skin biopsies, they used a non-invasive method that looks at the nerves in the eye (in vivo corneal confocal microscopy). They found evidenced of impaired heat detection and increased tortuosity of small fibers.
But in contrast to previous studies, no differences in small fiber...
it seems that the intervention was something that was made up, together with people living with Long Covid.
Not sure why this idea would warrant a trial of more than 500 people...
Meerpohl is also a member of the Governing Board so he might have been involved in the decision to cancel the planned update.
https://community.cochrane.org/organizational-info/people/governing-board/governing-board-membership
Just noticed that Joerg Meerpohl the director of Cochrane Germany who commented on the review in the German article was also a co-author of this rapid response with Paul Garner that accused NICE of a "disastrous misapplication of GRADE methodology."...
I thought the point of not wanting to retract Cochrane reviews was to keep reviewers happy and not offend them (so that researchers keep doing reviews for Cochrane).
But what they have done now with the IAG and new author team is arguably worse. They wasted their time and treated them with...
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.